doramapimod
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 1999 (NCT02208856)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Allosteric MAPK14 inhibitor. In addition to MAPK11, BIRB-796 has been shown to inhibit MAPK11, MAPK12 and MAPK13 (PMID:15755732).
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1- Mol. weight
- 527.67 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL103667 ↗
Also known as
- 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3(4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl)urea
- bibr 796 bs
- birb796
- birb 796
- birb-796
- birb-796
- birb 796 bs
- birb 796 bs
- doramapimod
- doramapimod
- doramapimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02214888 | Phase 2 | May 1, 2003 | Boehringer Ingelheim |
| NCT02211885 | Phase 1 | Oct 1, 2002 | Boehringer Ingelheim |
| NCT02211144 | Phase 1 | Mar 1, 2002 | Boehringer Ingelheim |
| NCT02209831 | Phase 1 | Nov 1, 2001 | Boehringer Ingelheim |
| NCT02209792 | Phase 2 | Oct 1, 2001 | Boehringer Ingelheim |
| NCT02209753 | Phase 2 | Jun 1, 2001 | Boehringer Ingelheim |
| NCT02209779 | Phase 2 | May 1, 2001 | Boehringer Ingelheim |
| NCT02209805 | Phase 1 | Jan 1, 2001 | Boehringer Ingelheim |
| NCT02211157 | Phase 1 | Mar 1, 2000 | Boehringer Ingelheim |
| NCT02211170 | Phase 1 | Feb 1, 2000 | Boehringer Ingelheim |
| NCT02208856 | Phase 1 | Sep 1, 1999 | Boehringer Ingelheim |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 11 | 11 | 2 | 1999 |
1 organizations
Page 1 / 1